Skip to content

Castle Biosciences CSTL Net Investment in Lease

Net Investment in Lease at other companies

Veracyte logo
VeracyteVCYT
Personalis, Inc. logo
Personalis, Inc.PSNL
NeoGenomics logo
NeoGenomicsNEO
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
GeneDx Holdings logo
GeneDx HoldingsWGS
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's net investment in lease?
Castle Biosciences (CSTL) reported net investment in lease of $14.42M in Q1 2026.
How has Castle Biosciences's net investment in lease changed year-over-year?
Castle Biosciences's net investment in lease increased by 29.2% year-over-year, from $11.16M to $14.42M.